There was no statistically significant difference between the pazopanib/pemetrexed and cisplatin/pemetrexed arms for PFS ( median PFS , 25.0 versus 22.9 weeks , respectively ; hazard ratio = 0.75 ; 95 % confidence interval , 0.43 % -1.28 % ; p = 0.26 ) or objective response rate ( 23 % versus 34 % , respectively ; 95 % confidence interval , -30.6 % to 7.2 % ; p = 0.21 ) .